Cashu
Vanda Pharmaceuticals Faces FDA Rejection of HETLIOZ® Amid Ongoing Regulatory Dispute
about 1 month ago
Stocks
Health Care
vnda
Vanda Pharmaceuticals
NASDAQ: VNDA
+2.41 (+41.84%)
8.17
USD
At close at Feb 23, 21:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
340.40M
Dividend Yield
0.00%
P/E Ratio
-1.54
EPS
-0.33
Revenue
198.77M
Avg. Volume
2.60M
About
What does VNDA do?
Vanda Pharmaceuticals, headquartered in Washington, D.C., develops therapies for unmet medical needs and has three commercial products, including HETLIOZ and Fanapt. The company also has multiple drugs in development.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.